Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2A) triggered mechanisms. A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist. All articles were reviewed in this topic and indexed in PubMed with keywords: Parkinson’s disease psychosis, serotonin 2a receptor inverse agonist, clozapine, quetiapine, pimavanserin.
Keywords: Clozapine, Parkinson's disease psychosis, pimavanserin, quetiapine, serotonin 2a receptor inverse agonist.
CNS & Neurological Disorders - Drug Targets
Title:Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
Volume: 16 Issue: 3
Author(s): Zsofia Majlath, Izabella Obal and Laszlo Vecsei*
Affiliation:
- Department of Neurology, University of Szeged, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, Semmelweis u. 6., H-6725 Szeged,Hungary
Keywords: Clozapine, Parkinson's disease psychosis, pimavanserin, quetiapine, serotonin 2a receptor inverse agonist.
Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2A) triggered mechanisms. A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist. All articles were reviewed in this topic and indexed in PubMed with keywords: Parkinson’s disease psychosis, serotonin 2a receptor inverse agonist, clozapine, quetiapine, pimavanserin.
Export Options
About this article
Cite this article as:
Majlath Zsofia, Obal Izabella and Vecsei Laszlo*, Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin, CNS & Neurological Disorders - Drug Targets 2017; 16 (3) . https://dx.doi.org/10.2174/1871527315666161006104347
DOI https://dx.doi.org/10.2174/1871527315666161006104347 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Hypotensive Agents from Verbesina Caracasana: Structure, Synthesis and Pharmacology
Current Medicinal Chemistry Metabolic Fate of Endocannabinoids
Current Neuropharmacology Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Current Medicinal Chemistry Rationale of Statin Therapy in Septic Patients
Current Vascular Pharmacology Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Innovative Therapeutic Strategies for Restoring Lymphocyte Functions in Septic Patients
Inflammation & Allergy - Drug Targets (Discontinued) Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Immunosuppressive Therapies in Solid Organ Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design Nitric Oxide in Asthma Therapy
Current Pharmaceutical Design Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets